References
- Lenneke EM, Thijsen SF, van Elden L, et al. Human metapneumovirus in adults. Viruses. 2013;5:87–110.
- Fuehner T, Dierich M, Duesberg C, et al. Single-centre experience with oral ribavirin in lung transplant recipients with paramyxovirus infections. Antiviral Ther. 2011;16:733–740.
- Kahn JS. Epidemiology of human metapneumovirus. Clin Microbiol Rev. 2006;19:546–557.
- Matsuzaki Y, Itagaki T, Ikeda T, et al. Human metapneumovirus infection among family members. Epidemiol Infect. 2013;141:827–832.
- Walsh EE, Peterson DR, Falsey AR. Human metapneumovirus infections in adults: another piece of the puzzle. Arch Intern Med. 2008;168:2489–2496.
- Wyde PR, Chetty SN, Jewell AM, et al. Comparison of the inhibition of human metapneumovirus and respiratory syncytial virus by ribavirin and immune serum globulin in vitro. Antiviral Res. 2003;60:51–59.
- McCurdy LH, Milstone A, Dummer S. Clinical features and outcomes of paramyxoviral infection in lung transplant recipients treated with ribavirin. J Heart Lung Transplant. 2003;22:745–753.
- Raza K, Ismailjee SB, Crespo M, et al. Successful outcome of human metapneumovirus (hMPV) pneumonia in a lung transplant recipient treated with intravenous ribavirin. J Heart Lung Transplant. 2007;26:862–864.
- Renaud C, Xie H, Seo S, et al. Mortality rates of human metapneumovirus and respiratory syncytial virus lower respiratory tract infections in hematopoietic cell transplantation recipients. Biol Blood Marrow Transplant. 2013;19:1220–1226.
- Park SY, Baek S, Lee SO, et al. Efficacy of oral ribavirin in hematologic disease patients with paramyxovirus infection: analytic strategy using propensity scores. Antimicrob Agents Chemother. 2013;57:983–989.
- Schuurmans MM, Benden C, Huber LC. Managing viral respiratory tract infections in lung transplant recipients. Eurasian J Pulmonol. 2014;16:144–149.
- WHO. Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. WHO/NMH/NHD/MNM/11.1; 2011.
- Talaat KR, Karron RA, Thumar B, et al. Experimental infection of adults with recombinant wild-type human metapneumovirus. J Infect Dis. 2013;208:1669–1678.
- Preiksaitis CM, Kuypers JM, Fishera CE, et al. A patient self-collection method for longitudinal monitoring of respiratory virus infection in solid organ transplant recipients. J Clin Virol. 2015;62:98–102.
- De Lima CR, Mirandolli TB, Carneiro LC, et al. Prolonged respiratory viral shedding in transplant patients. Transpl Infect Dis. 2014;16:165–169.
- Hopkins P, McNeil K, Kermeen F, et al. Human metapneumovirus in lung transplant recipients and comparison to respiratory syncytial virus. Am J Respir Crit Care Med. 2008;178:876–881.
- Glanville AR, Scott AI, Morton JM, et al. Intravenous ribavirin is a safe and cost-effective treatment for respiratory syncytial virus infection after lung transplantation. J Heart Lung Transplant. 2005;24:2114–2119.
- Gross AE, Bryson ML. Oral ribavirin for the treatment of noninfluenza respiratory viral infections: a systematic review. Ann Pharmacother. 2015;49:1125–1135.
- Kamar N, Izopet J, Tripon S, et al. Ribavirin for chronic hepatitis E virus infection in transplant recipients. N Engl J Med. 2014;370:1111–1120.
- Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239–245.
- Bridevaux PO, Aubert JD, Soccal PM, et al. Incidence and outcomes of respiratory viral infections in lung transplant recipients: a prospective study. Thorax. 2014;69:32–38.
- Shahda S, Carlos WG, Kiel PJ, et al. The human metapneumovirus: a case series and review of the literature. Transpl Infect Dis. 2011;13:324–328.
- Fisher CE, Preiksaitis CM, Lease ED, et al. Symptomatic respiratory virus infection and chronic lung allograft dysfunction. Clin Infect Dis. 2016;62:313–319.
- Dosanjh A. Respiratory metapneumoviral infection without co-infection in association with acute and chronic lung allograft dysfunction. J Inflamm Res. 2015;8:79–82.